Melanotan I (afamelanotide)
Melanotan-1, MT-I, MT-1, CUV1647, Nle4-D-Phe7-α-MSH, Scenesse, EI-_05x (Epitan)
The Ground Truth Score
four plain questions, never one numberFDA-approved for a rare disease; thin evidence for the tanning use people actually want it for.
Bottom line
The genuine rare high-evidence peptide, two phase III RCTs and FDA approval for erythropoietic protoporphyria, but that grade does NOT transfer to the cosmetic tanning use, where evidence is only small open-label pilots and the product is a gray-market injectable.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
Can you legally get it?
FDA-approvedPrescription medicineAn approved drug with a label, a manufacturer, and a prescribing route. This is the only tier where what is in the vial is guaranteed by anyone. Check the indication, though: approval is always for something specific, and it is rarely the use this compound is popular for.
Afamelanotide is FDA-approved (Oct 8 2019) as SCENESSE, a 16 mg subcutaneous IMPLANT for erythropoietic protoporphyria, and EMA-approved since 2014. Hold both halves of that: the approval is real and rests on phase III RCTs, and it is for a rare photosensitivity disorder via an implant placed by a clinician. The injectable vials sold for tanning are not SCENESSE, and the tanning use is not what was approved.
Legal status as of 2026-06-16. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓APPROVED (not a recommendation to self-use): one SCENESSE implant containing 16 mg afamelanotide, inserted subcutaneously above the anterior supra-iliac crest by a trained provider every 2 months.
Reported, not prescribed. Verify your vial and your math.
First documented human use
First controlled human use 1991 (Levine et al., JAMA. SC α-MSH analogue induced measurable tanning in volunteers); formal pharmacokinetic/dose-ranging human studies 1996 (Dorr/Levine, skin types III-IV). This is one of the few peptides where the question is genuinely settled: pivotal phase III RCTs were completed and the drug is FDA-approved (Oct 8, 2019, for EPP).
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.
- Increases eumelanin (the photoprotective pigment) in skin without UV exposure by agonizing the MC1 receptor
- Lets EPP patients tolerate far more pain-free light, restoring quality of life in a disease with no prior effective treatment
- A 'natural-looking,' gradual tan with none of the sexual side effects of its cousin Melanotan II
- Backed by real FDA approval and an EMA approval, not vaporware peptide marketing
The data behind each bullet
What actually backs it
FDA-approved (Oct 8, 2019) as the SCENESSE 16 mg subcutaneous implant to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).
FDA approval based on two randomized, double-blind, placebo-controlled phase III trials. EMA-approved since 2014. Orphan/rare-disease indication.
FDA Drugs@FDA. SCENESSE (afamelanotide) NDA 210797 ↗In the U.S. phase III RCT, median pain-free direct-sunlight exposure was 69.4 h with afamelanotide vs 40.8 h placebo (P=0.04); the EU trial showed 6.0 h vs 0.8 h (P=0.005) over the study period.
Two multicenter double-blind placebo-controlled RCTs, n=168 total (86 drug / 81 placebo), published NEJM 2015;373:48-59. Quality-of-life and phototoxic-reaction secondary endpoints also favored drug.
PubMed. Langendonk et al., NEJM 2015, Afamelanotide for EPP ↗Off-label/cosmetic tanning: it does produce melanin-independent tanning in healthy volunteers, but the human tanning evidence is only small open-label dose-ranging pilots (single-digit subject counts), not controlled efficacy or safety trials.
Original 1991-1999 open-label studies (Levine JAMA 1991; Dorr 1996 PK; dose-ranging n=8). No randomized controlled trial has ever tested or approved afamelanotide for cosmetic tanning; gray-market injectable MT-I is unregulated and often mislabeled vs Melanotan II.
PubMed. Dorr et al. 1996, Skin pigmentation & PK of melanotan-I in humans ↗Investigational for vitiligo (with NB-UVB) and previously trialed for polymorphous light eruption; vitiligo phase III (CUV105) ongoing with results expected H2 2026.
Active and prior company-sponsored phase III programs; vitiligo data not yet final, PLE program did not yield approval. Promising but unproven for these uses.
ClinicalTrials.gov, afamelanotide vitiligo / PLE trials ↗Sexual side effects (spontaneous erections, libido changes) belong to Melanotan II, not Melanotan I, a key confound, since gray-market vendors and forums routinely mix up or mislabel the two.
MT-II is the cyclic non-selective melanocortin agonist responsible for the famous self-injection erection anecdote and PT-141/bremelanotide lineage; MT-I (linear, MC1R-predominant) is not associated with sexual effects per clinical reports.
PubMed search, melanotan adverse effects review ↗Prove it
Can you tell if it's working?
The honest test: if it's working, is there any objective way to see it — a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.
Skin melanin index by reflectance colorimetry, read at a UV-shielded site, is the direct objective proof it works — darkening at a covered site can only come from the drug.
Bloodwork
Nothing on a routine panel confirms this one. Anyone who says otherwise is guessing.
Melanotan-1 (afamelanotide) is an alpha-MSH analog and MC1R agonist that drives eumelanin synthesis in skin melanocytes; its therapeutic action is local cutaneous pigmentation/photoprotection, which produces no measurable circulating analyte. In the pivotal EPP randomized trials it did not lower the disease's own biomarker (erythrocyte/plasma protoporphyrin) or alter liver biochemistries, so no routine bloodwork can confirm it is working.
Read this before you spend on labs
Bloodwork cannot verify melanotan-1. Its effect is cutaneous — increased eumelanin (tanning) and, in erythropoietic protoporphyria, longer pain-free sunlight exposure. Response is judged visually / by skin-reflectance and by light-tolerance and phototoxicity symptoms, not by any serum test. No routine LabCorp/Quest analyte reflects melanin synthesis, and in the randomized EPP trials afamelanotide did not lower erythrocyte protoporphyrin, plasma protoporphyrin, or alter liver biochemistries versus baseline — so even the disease's own biomarker does not track efficacy. Track it on the skin and by symptoms, not in a tube.
Other ways to track it
Skin reflectance colorimetry / melanin index (dermatology-grade Mexameter or DSM-II ColorMeter at a clinic; standardized fixed-lighting before/after photos of a sun-shielded site as a lower-fidelity home proxy)
A working result shows a measurable rise in melanin index (a darker reflectance reading) at a fixed, UV-shielded body site such as the inner upper arm or buttock, with no sun exposure. Because the site is covered, any darkening can only come from the drug, not tanning. This is the actual therapeutic effect, not a proxy for it.
Melanotan-1 (afamelanotide) is an MC1R agonist that drives UV-independent eumelanin synthesis in melanocytes. Increased cutaneous melanin is precisely the effect the drug produces, and reflectance melanin density is the same class of readout used to quantify afamelanotide's effect in human trials, so a colorimeter measures efficacy directly.
Bottom line
The effect is purely cutaneous, and that is exactly why it is trackable: skin melanin index by reflectance colorimetry at a sun-shielded site is a genuine DIRECT objective efficacy readout (the Ground Truth page confirms there is no blood proxy). Nothing in urine, stool, sleep/wearable, CGM, VO2max, or DEXA applies — melanotan-1 does not move metabolic, body-composition, or recovery markers. MC1R genotype was dropped: it is a real and mechanistically sound responder predictor, but it is static and cannot confirm that any given course actually worked, so it is not a tracking channel. If you cannot measure pigmentation at a covered site, you have no objective confirmation.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data — bring your own numbers.
How to track it →Mechanism
How it's assumed to work
Synthetic linear analogue of α-melanocyte-stimulating hormone (α-MSH); agonizes the melanocortin-1 receptor (MC1R) on melanocytes, driving eumelanin synthesis independently of UV, plus antioxidant, DNA-repair-enhancing, and anti-inflammatory effects. Substitutions (Nle4, D-Phe7) make it ~resistant to enzymatic degradation, giving a far longer half-life than native α-MSH. Mechanism is established (approved drug), not assumed.
Dosing & handling
What users and clinicians report
APPROVED (not a recommendation to self-use): one SCENESSE implant containing 16 mg afamelanotide, inserted subcutaneously above the anterior supra-iliac crest by a trained provider every 2 months. Gray-market off-label users report reconstituted SC injections in the ~0.5-1 mg/day range during a 'loading' phase then less frequent maintenance, but this is unverified, unregulated, and outside any controlled trial. Original human dose-ranging used ~0.16 mg/kg/day SC.
Doses are REPORTED, not prescribed. Only the 16 mg bimonthly implant is studied and approved, and only for EPP under medical supervision. Injectable 'Melanotan 1' from peptide vendors has no established dose, no purity guarantee, and is frequently mislabeled, never assume vial contents match the label. Confirm any product identity before use.
Timing & food
Approved implant is dosed every 2 months independent of food (it is not oral; afamelanotide has zero oral bioavailability). For the implant, timing is driven by the start of high-light-exposure seasons in EPP. Gray-market injectors often dose in the evening to sleep through nausea/flushing, but there is no food-timing rationale because it is parenteral and the effect is cumulative pigment build-up, not acute.
Half-life
Apparent half-life ~15 hours from the controlled-release SC implant; median Tmax ~36 h, mean Cmax ~3.7 ng/mL. Drug is generally undetectable in plasma within ~2-3 days of implant placement, while the pigmentation effect persists for weeks (hence the 2-month dosing interval). Native α-MSH, by contrast, degrades within minutes.
Reconstitution sensitivity
The approved product is a solid bioresorbable implant (no reconstitution). For gray-market lyophilized injectable powder, peptide-handling norms apply: reconstitute gently with bacteriostatic water, do not shake, refrigerate after mixing, protect from light and heat. Reconstitution quality is unverifiable for unregulated product, which is itself a core risk.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Moderate-to-high chatter, but skewed: most online volume is about Melanotan II (the stronger tanning + libido peptide) and PT-141, with MT-I discussed comparatively less and frequently confused with MT-II. EPP-patient communities (e.g., porphyria foundations) discuss the approved drug seriously and separately from the tanning crowd.
Consistency
Mixed/inconsistent. EPP patient and clinical sources are consistent and positive about real benefit. The tanning-forum signal is muddier: users agree MT-I tans more slowly and 'cleaner' than MT-II (fewer side effects) but many find it underwhelming versus MT-II and pivot to the stronger compound, so the cosmetic signal partly self-selects toward its sibling.
Source credibility
Two-tier. High-credibility: peer-reviewed trials, FDA/EMA, and disease-foundation sources for the EPP indication. Low-credibility: most tanning-peptide vendor sites and 'peptide wiki' pages are affiliate/commercial, conflate MT-I and MT-II, and recite dosing with no controlled-trial basis, discount these heavily.
- EPP patients and porphyria communities broadly report genuine, life-changing increases in tolerable sun/light exposure, among the most credible positive signals for any peptide, backed by the trials.
- Cosmetic-tanning users say MT-I builds a slower, more natural-looking tan than Melanotan II and lacks the nausea/flush/erection effects, but many find it 'too mild' and switch to MT-II for faster results.
- Recurring complaints across off-label users: new or darkening moles and freckles, uneven pigmentation, and nausea/flushing during loading, plus persistent confusion over whether vendor 'MT-1' is actually MT-2.
- Skeptical/clinical voices repeatedly warn that the gray-market injectable is unregulated, frequently mislabeled, and that long-term melanoma risk is unknown, and that the FDA approval applies only to the EPP implant, not to buying it online to tan.
Placebo risk, Low
Placebo risk is LOW because the core endpoint is objective and measurable: increased skin melanin/pigmentation (visibly darker skin, measurable by reflectance) and, in EPP, photoprovocation tolerance and recorded pain-free light hours under double-blind RCT conditions. Skin doesn't darken by belief. (Subjective comfort/QoL components carry some placebo susceptibility, but the pigmentation readout anchors it.)
Risk panel
What could go wrong
Adverse events
In the regulated implant: implant-site reactions ~21% (mainly discoloration/pain/erythema/hematoma), nausea ~19%, headache ~20%, plus oropharyngeal pain, fatigue, dizziness, somnolence, and skin/mucosal hyperpigmentation. Generalized skin darkening and darkening/new melanocytic nevi occur, full-body skin exams are advised twice yearly. No drug-related serious adverse events in the pivotal trials.
Theoretical concerns
Because MC1R agonism darkens existing nevi and stimulates melanocytes, there is a theoretical (unquantified) concern about masking or promoting melanoma; long-term carcinogenicity data are limited and monitoring is mandated rather than reassured. Generalized hyperpigmentation is cosmetically irreversible until the drug clears.
Contraindications
Approved only for adults; hepatic/renal impairment not formally studied (caution). The label mandates periodic full-body dermatologic surveillance. Not indicated or studied in pregnancy/lactation. As an implant, requires trained in-office insertion.
Honest unknowns
The dominant real-world risk is NOT the approved drug, it is the gray-market injectable 'Melanotan 1' sold online and in gyms: unverified identity/purity, frequently conflated with or substituted by Melanotan II (which adds nausea, priapism, and cardiovascular effects), non-sterile reconstitution, and self-injection. Long-term melanoma risk of chronic off-label use is genuinely unknown.
Confound watch
Three big confounds: (1) MT-I vs MT-II conflation, sexual side effects, the worst safety case reports (priapism, rhabdomyolysis, AKI, renal infarction, melanoma case reports), and 'fat loss/libido' claims belong to non-selective MT-II, not MT-I; (2) the FDA halo, grade A is for EPP photoprotection, not for cosmetic tanning, where evidence is a handful of open-label volunteers; (3) tanning is self-reinforcing, users sun-expose more, which independently darkens skin, inflating perceived drug effect.
History
Discovery → first use → status
- Early 1980sSynthesized at University of Arizona (Hruby, Hadley, Levine) as a stable α-MSH analogue; hypothesis was a UV-free protective tan to reduce skin-cancer risk.
- 1991First controlled human demonstration of induced tanning via SC α-MSH analogue (Levine et al., JAMA).
- 1996Human pharmacokinetic / dose-ranging studies (Dorr, Levine) establish SC bioavailability and tanning at modest doses.
- 2005-2006Licensed to Australian biotech Epitan, which renamed to Clinuvel; compound designated CUV1647, then INN 'afamelanotide.'
- 2007-2011Phase II/III program in EPP (and PLE); pivotal EU trial Jan 2010-May 2011, U.S. trial May 2012-Jul 2013.
- 2014EMA approval as SCENESSE for EPP in the EU.
- Jul 2015Pivotal phase III RCT results published in NEJM.
- Oct 8, 2019FDA approves SCENESSE implant for EPP, first approved treatment for the disease.
- 2025-2026EMA expands to year-round dosing; vitiligo phase III (CUV105) readout expected H2 2026.
Verification
The COA standard, applied
Approval verified against FDA Drugs@FDA (NDA 210797, approved 2019-10-08) and DailyMed/EMA labeling; efficacy verified against the peer-reviewed NEJM 2015 phase III RCT (PMC4780255) with exact endpoints and p-values; tanning evidence verified against the original 1991/1996 human studies (PMID 9113347). Adverse-event percentages cross-checked between FDA review and EMA SmPC. MT-I vs MT-II distinction verified across DermNet and review literature.
The full verification standard →Sources
Where this comes from
- FDA Drugs@FDA. SCENESSE (afamelanotide) NDA 210797 ↗· Primary regulatory record; FDA approval 2019-10-08 for EPP.
- DailyMed. SCENESSE (afamelanotide) implant label ↗· Official prescribing information: indication, dosing, adverse reactions, monitoring.
- PubMed. Langendonk et al., NEJM 2015, Afamelanotide for EPP (phase III RCTs) ↗· Pivotal double-blind placebo-controlled trials; exact endpoints and p-values.
- PMC. Afamelanotide for EPP, full text (PMC4780255) ↗· Open-access full trial report with detailed results and adverse events.
- PubMed. Dorr et al. 1996, Skin pigmentation & pharmacokinetics of melanotan-I in humans ↗· Original human PK/tanning data; anchors first-human-use and dosing history.
- ClinicalTrials.gov, afamelanotide trials (EPP, vitiligo, PLE) ↗· Registry of pivotal and ongoing investigational programs.
- PubMed, afamelanotide review in EPP (Markham, Drugs 2016) ↗· Independent drug review summarizing efficacy/safety.
- NCBI LiverTox. Afamelanotide ↗· NIH safety monograph; hepatotoxicity and class context.
- DermNet NZ. Melanotan ↗· Clinical dermatology source distinguishing MT-I vs MT-II and gray-market risks.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.